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Background
Apixaban, an oral, direct factor Xa inhibitor, may reduce the risk of recurrent ische mic 
events when added to antiplatelet therapy after an acute coronary syndrome.
Methods
We conducted a randomized, double-blind, placebo-controlled clinical trial comparing 
apixaban, at a dose of 5 mg twice daily, with placebo, in addition to standard anti-
platelet therapy, in patients with a recent acute coronary syndrome and at least two 
additional risk factors for recurrent ischemic events.
Results
The trial was terminated prematurely after recruitment of 7392 patients because of an 
increase in major bleeding events with apixaban in the absence of a counterbalanc-
ing reduction in recurrent ischemic events. With a median follow-up of 241 days, 
the primary outcome of cardiovascular death, myocardial infarction, or ischemic 
stroke occurred in 279 of the 3705 patients (7.5%) assigned to apixaban (13.2 events 
per 100 patient-years) and in 293 of the 3687 patients (7.9%) assigned to placebo 
(14.0 events per 100 patient-years) (hazard ratio with apixaban, 0.95; 95% confidence 
interval [CI], 0.80 to 1.11; P = 0.51). The primary safety outcome of major bleeding 
according to the Thrombolysis in Myocardial Infarction (TIMI) definition occurred 
in 46 of the 3673 patients (1.3%) who received at least one dose of apixaban (2.4 events 
per 100 patient-years) and in 18 of the 3642 patients (0.5%) who received at least one 
dose of placebo (0.9 events per 100 patient-years) (hazard ratio with apixaban, 2.59; 
95% CI, 1.50 to 4.46; P = 0.001). A greater number of intracranial and fatal bleeding 
events occurred with apixaban than with placebo.
Conclusions
The addition of apixaban, at a dose of 5 mg twice daily, to antiplatelet therapy in high-
risk patients after an acute coronary syndrome increased the number of major bleeding 
events without a significant reduction in recurrent ischemic events. (Funded by Bristol-
Myers Squibb and Pfizer; APPRAISE-2 ClinicalTrials.gov number, NCT00831441.)
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Patients with acute coronary syn-dromes frequently have recurrent ischemic events despite the use of currently recom-
mended antiplatelet therapy, revascularization pro-
cedures as appropriate, and other evidence-based 
secondary preventive measures.1-3 Oral anticoagu-
lation therapy with vitamin K antagonists reduces 
the incidence of recurrent ischemic events after 
myocardial infarction but also increases the risk of 
bleeding when it is added to aspirin or aspirin and 
clopidogrel.4-9
Apixaban, an orally active, selective, direct fac-
tor Xa inhibitor, has been shown to reduce the in-
cidence of venous thromboembolism in patients 
undergoing orthopedic surgery and to prevent 
thromboembolic events in patients with atrial 
fibrillation who are not candidates for oral vita-
min K antagonist therapy.10-15 We previously stud-
ied the use of apixaban, at doses of 5 to 20 mg 
daily, in patients who had had recent acute coro-
nary syndromes and who were receiving aspirin 
or aspirin plus clopidogrel.16 Treatment with apix-
aban resulted in dose-related increases in bleeding 
events and a trend toward fewer is chemic events. 
Considering both ischemic events and bleeding 
events, the preferred dose was thought to be 10 mg 
daily. Similar findings were observed with another 
factor Xa inhibitor, rivaroxaban, in a similar popu-
lation.17 We therefore conducted a phase 3 trial to 
determine whether, in high-risk patients with an 
acute coronary syndrome, the benefit of apixaban 
in reducing ischemic events would outweigh the 
increased risk of bleeding.
Me thods
Study Design
The Apixaban for Prevention of Acute Ischemic 
Events 2 (APPRAISE-2) trial was a double-blind, 
placebo-controlled, randomized clinical trial con-
ducted at 858 sites in 39 countries. The study was 
approved by the institutional review board at each 
participating site. All participating patients gave 
written informed consent. The trial was supervised 
by a steering committee (see the Supplementary Ap-
pendix, available with the full text of this article 
at NEJM.org) that included representatives from 
the sponsors (Bristol-Myers Squibb and Pfizer). 
The data were managed and all analyses were per-
formed at the Duke Clinical Research Institute, 
Durham, North Carolina. All the authors designed 
the study, reviewed the data, participated in the 
analyses, and assume responsibility for the com-
pleteness and accuracy of the data and analyses 
and for the fidelity of the study to the protocol. 
The first author wrote the first draft of the manu-
script, and all the authors provided comments on 
subsequent drafts and made the decision to sub-
mit the manuscript for publication. The trial pro-
tocol and statistical analysis plan are available at 
NEJM.org. The sponsors provided the drugs for 
the study.
Study Population
The main inclusion criterion for the trial was an 
acute coronary syndrome (myocardial infarction, 
with or without ST-segment elevation, or unstable 
angina) within the previous 7 days, with symptoms 
of myocardial ischemia lasting 10 minutes or more 
with the patient at rest plus either elevated levels of 
cardiac biomarkers or dynamic ST-segment depres-
sion or elevation of 0.1 mV or more. Patients who 
met this criterion were eligible for the study if their 
condition was clinically stable and they were re-
ceiving standard treatment after the acute coronary 
syndrome, including aspirin or aspirin plus any 
P2Y12-receptor antagonist. Eligible patients were 
also required to have two or more of the following 
high-risk characteristics: an age of at least 65 years, 
diabetes mellitus, myocardial infarction within the 
previous 5 years, cerebrovascular disease, periph-
eral vascular disease, clinical heart failure or a left 
ventricular ejection fraction of less than 40% in as-
sociation with the index event, impaired renal func-
tion with a calculated creatinine clearance of less 
than 60 ml per minute, and no revascularization 
after the index event. Exclusion criteria are listed 
in the Supplementary Appendix.
Randomization and Study Regimen
Patients were randomly assigned, in a 1:1 ratio, 
to receive apixaban, at a dose of 5 mg twice daily, 
or matching placebo. Patients with an estimated 
creatinine clearance of less than 40 ml per minute 
at the time of randomization were randomly as-
signed to receive apixaban at a dose of 2.5 mg twice 
daily or matching placebo. Randomization was per-
formed in a blinded fashion with the use of an in-
teractive voice-response system, in permuted blocks 
of two, stratified according to site and according to 
planned long-term use of aspirin or aspirin plus a 
P2Y12-receptor antagonist. Patients who interrupted 
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the study regimen during the course of the trial 
were encouraged to resume taking the assigned 
drug if and when possible.
Investigators were encouraged to practice evi-
dence-based medicine and follow appropriate clin-
ical practice guidelines in managing the care of 
their patients. The use, choices, and duration of 
antiplatelet therapy, as well as decisions about the 
use of other medical treatments and subsequent 
revascularization procedures, were left to the dis-
cretion of the treating physicians.
Study Outcomes
The primary efficacy outcome was the composite 
of cardiovascular death, myocardial infarction, or 
ischemic stroke.18 The primary safety outcome was 
major bleeding, according to the Thrombolysis in 
Myocardial Infarction (TIMI) definition.19
Prespecified secondary outcomes included the 
composite of cardiovascular death, myocardial in-
farction, ischemic stroke, or unstable angina; the 
composite of cardiovascular death, myocardial in-
farction, ischemic or hemorrhagic stroke, or fatal 
bleeding; and the composite of death from any 
cause, myocardial infarction, or ischemic or hem-
orrhagic stroke. Additional efficacy outcomes in-
cluded the individual components of the primary 
efficacy outcome, unstable angina, and stent 
thrombosis.20 Additional safety outcomes included 
TIMI major or minor bleeding, major or clinically 
relevant nonmajor bleeding according to the Inter-
national Society on Thrombosis and Haemostasis 
(ISTH) definitions, and severe or moderate bleed-
ing according to the Global Use of Strategies to 
Open Occluded Coronary Arteries (GUSTO) def-
initions.21,22 Data on adverse events other than 
bleeding were also collected.
The primary and secondary efficacy outcomes 
and the main safety outcome were adjudicated 
with the use of prespecified criteria by an inde-
pendent clinical events committee whose members 
were unaware of the group assignments. Detailed 
definitions of outcome events are provided in the 
Supplementary Appendix.
Statistical Analysis
Assuming a recruitment period of approxi mately 
2 years, an average follow-up period of 1.25 years, 
and a rate of the primary efficacy outcome of 8% 
per year, we estimated that we would need to en-
roll 10,800 patients to achieve the desired target 
of 938 patients with a primary efficacy outcome. 
With this number of patients with events, we es-
timated that the study would have 80% power to 
detect a 20% reduction in relative risk with apixa-
ban as compared with placebo at a one-sided al-
pha level of 0.005 and 93% power to detect the 
same reduction in risk at a one-sided alpha level 
of 0.025.
In November 2010, after approximately 7000 
patients had been recruited, the independent 
data monitoring committee recommended that 
the trial be stopped, owing to an excess of clin-
ically important bleeding events with apixaban 
in the absence of a counterbalancing reduction 
in ischemic events. Recruitment was stopped on 
November 18, 2010. All the patients enrolled in 
the study were contacted and told to discon-
tinue the study drug and schedule a final follow-
up assessment. The trial database was locked on 
March 23, 2011.
The intended treatment period, starting on the 
day of randomization and ending at the efficacy 
cutoff date (November 18, 2010), is the basis for 
the efficacy analyses. The actual treatment period, 
starting on the date the first dose of study drug 
was administered and ending 2 days after the last 
dose of study drug was administered, is the basis 
for the analyses of safety. A post hoc analysis was 
performed to assess the primary efficacy outcome 
during the actual treatment period.
Efficacy and bleeding outcomes were analyzed 
with the use of a Cox proportional-hazards model 
that included the assigned study group as a co-
variate and that was stratified according to anti-
platelet therapy (single or dual) at baseline. Data 
on patients who died of noncardiovascular causes 
were censored at the time of death. A point esti-
mate and two-sided 95% confidence interval for 
the hazard ratio were calculated for each outcome. 
Prespecified efficacy and safety analyses were per-
formed in subgroups according to baseline anti-
platelet therapy, type of acute coronary syndrome, 
treatment for acute coronary syndrome, dose of 
apixaban, region, age, sex, race, body-mass index, 
degree of renal impairment, number of risk fac-
tors, presence or absence of diabetes mellitus, and 
presence or absence of heart failure. The rates of 
efficacy and bleeding events are reported as per-
centages and as events per 100 patient-years. Other 
categorical variables are reported as percentages. 
All P values are two-sided. All analyses were per-
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formed with the use of SAS software, version 9.0 
(SAS Institute).
R esult s
Study Participants
A total of 7392 patients underwent randomization 
between March 17, 2009, and November 18, 2010 
(Fig. 1 in the Supplementary Appendix). Patients 
underwent randomization a median of 6 days (inter-
quartile range, 4 to 7) after the index event of acute 
coronary syndrome and 2 days (interquartile range, 
2 to 4) after discontinuation of parenteral anti-
thrombotic therapy. Among the patients who 
underwent randomization, 81 (1.1%) withdrew 
consent and 50 (0.7%) were lost to follow-up for 
the primary outcome during the intended treat-
ment period. The median duration of follow-up 
from the time of randomization through the 
last date of contact in the study was 240 days 
(interquartile range, 132 to 352) among patients 
assigned to apixaban and 242 days (interquartile 
range, 131 to 352) among patients assigned to 
placebo.
By design, the trial population had high rates 
of diabetes, prior myocardial infarction, cerebro-
vascular and peripheral vascular disease, heart fail-
ure or left ventricular dysfunction, and impaired 
renal function, and a large proportion of the pa-
tients had not undergone revascularization for the 
index event (Table 1). More than half the patients 
had three or more protocol-defined high-risk char-
acteristics at the time of enrollment.
The index event was a myocardial infarction 
with ST-segment elevation in approximately 40% 
of patients, a myocardial infarction without ST-
segment elevation in 42%, and unstable angina 
in 18% (Table 1). More than 52% of the patients 
underwent coronary angiography, 44% underwent 
a percutaneous coronary intervention, and 55% 
had their condition managed medically.
At the time of randomization, nearly all the 
patients (97%) were taking aspirin. The majority 
of the patients (81%) were receiving aspirin plus 
a P2Y12-receptor antagonist, predominantly clo-
pid ogrel. Most patients were receiving other ev-
idence-based therapies as well, and the rates of 
these therapies were similar in the apixaban and 
placebo groups.
Study Drug and Antiplatelet Therapies
A total of 7315 of the 7392 patients who under-
went randomization (99.0%) received at least one 
dose of the assigned study drug; 8.5% of the pa-
tients were assigned to the reduced dose of apix-
aban or matching placebo. Of these 7315 patients, 
863 of the 3673 patients who received at least one 
dose of apixaban (23.5%) and 746 of the 3642 who 
received at least one dose of placebo (20.5%) stopped 
taking the study drug before the end of the trial 
(P = 0.002). The median exposure to the study drug 
was 175 days (interquartile range, 66 to 293) among 
patients receiving apixaban and 185 days (inter-
quartile range, 75 to 298) among patients receiv-
ing placebo. The most common reasons for dis-
continuation of the study drug were adverse events 
(8.5% in the apixaban group vs. 6.5% in the pla-
cebo group) and withdrawal of consent (5.3% vs. 
4.2%). A total of 1310 (21.5%) of the patients who 
were taking aspirin plus a P2Y12-receptor antago-
nist at the time of randomization stopped taking 
the P2Y12-receptor antagonist during the course 
of the trial, at a median of 39 days (interquartile 
range, 13 to 108) after randomization; 135 (11.1%) 
of the patients receiving aspirin alone at random-
ization started taking a P2Y12-receptor antagonist 
during the trial, at a median of 14 days (interquar-
tile range, 4 to 93) after randomization.
Efficacy Outcomes
The final number of primary efficacy events was 
572, or 61.0% of the initially planned number. In 
the intention-to-treat analysis, the primary efficacy 
outcome of cardiovascular death, myocardial in-
farction, or ischemic stroke occurred in 279 pa-
tients (7.5%) assigned to apixaban (13.2 events per 
100 patient-years) and in 293 patients (7.9%) as-
signed to placebo (14.0 events per 100 patient-years) 
(hazard ratio with apixaban, 0.95; 95% confidence 
interval [CI], 0.80 to 1.11; P = 0.51) (Fig. 1 and 
Table 2). Similar results were seen in an on-treat-
ment analysis (218 vs. 249 events; hazard ratio, 
0.89; 95% CI, 0.74 to 1.06; P = 0.19). There were 
also no significant differences between the apix-
aban and placebo groups with respect to any of 
the secondary efficacy outcomes (Table 2).
The effect of apixaban as compared with pla-
cebo was similar among patients receiving com-
bination antiplatelet therapy and among those 
receiving aspirin alone. The rates of the primary 
efficacy outcome among patients who were re-
ceiving combination antiplatelet therapy were 7.2% 
in the apixaban group and 7.5% in the placebo 
group (hazard ratio with apixaban, 0.95; 95% CI, 
0.79 to 1.15), and the corresponding rates among 
those receiving aspirin alone were 9.0% and 9.8% 
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(hazard ratio, 0.92; 95% CI, 0.66 to 1.29) (P = 0.87 
for interaction). Similar findings with respect to 
the primary efficacy outcome were seen in all key 
subgroups (Fig. 2 in the Supplementary Appendix).
Bleeding and Other Safety Outcomes
In the on-treatment analysis, the primary safety 
outcome of TIMI major bleeding occurred in 46 
of the 3673 patients (1.3%) who received at least 
Table 1. Baseline Characteristics of the Study Patients.*
Variable Apixaban (N = 3705) Placebo (N = 3687)
Demographic characteristics
Age — yr
Median 67 67
Interquartile range 59–73 58–74
Female sex — no. (%) 1209 (32.6) 1169 (31.7)
Risk factors specified as inclusion criteria — no. (%)†
Age ≥65 yr 2179 (58.8) 2175 (59.0)
History of diabetes mellitus 1804 (48.7) 1732 (47.0)
Myocardial infarction within the previous 5 yr 923 (24.9) 1013 (27.5)
History of cerebrovascular disease 378 (10.2) 364 (9.9)
History of peripheral vascular disease 664 (17.9) 674 (18.3)
Heart failure or LVEF <40% associated with index ACS event 1489 (40.2) 1480 (40.1)
History of impaired renal function 1048 (28.3) 1089 (29.5)
No revascularization for index ACS event 2061 (55.6) 2034 (55.2)
Other medical history — no. (%)
Heart failure 1023 (27.6) 1053 (28.6)
Prior coronary revascularization 1030 (27.8) 1060 (28.7)
Index ACS event
Time from event to randomization — days
Median 6.0 6.0
Interquartile range 4.0–7.0 4.0–7.0
Type of event — no. (%)
ST-segment elevation myocardial infarction 1474 (39.8) 1453 (39.4)
Non–ST-segment elevation myocardial infarction 1533 (41.4) 1541 (41.8)
Unstable angina 673 (18.2) 667 (18.1)
Elevated cardiac markers — no. (%)‡ 3007 (81.2) 2994 (81.2)
Management of event — no. (%)
Coronary angiography 1923 (51.9) 1927 (52.3)
PCI 1624 (43.8) 1631 (44.2)
CABG 22 (0.6) 23 (0.6)
Medical therapy only 2061 (55.6) 2034 (55.2)
Use of parenteral antithrombotic agents — no. (%) 2972 (80.2) 2992 (81.1)
Selected medications — no. (%)
Angiotensin-converting–enzyme inhibitor 2434 (65.7) 2406 (65.3)
Angiotensin-receptor blocker 527 (14.2) 503 (13.6)
Beta-blocker 2853 (77.0) 2816 (76.4)
Statin 3076 (83.0) 3105 (84.2)
Proton-pump inhibitor 894 (24.1) 906 (24.6)
* All baseline characteristics were well matched between the two groups (P>0.05). ACS denotes acute coronary syndrome, 
CABG coronary-artery bypass grafting, LVEF left ventricular ejection fraction, and PCI percutaneous coronary intervention.
† To be eligible for inclusion in the study, patients had to have two or more of these risk factors.
‡ The cardiac markers assessed included the MB fraction of creatine kinase and troponin T or I.
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one dose of apixaban (2.4 events per 100 patient-
years), as compared with 18 of the 3642 patients 
(0.5%) who received at least one dose of placebo 
(0.9 events per 100 patient-years) (hazard ratio with 
apixaban, 2.59; 95% CI, 1.50 to 4.46; P = 0.001) 
(Table 2 and Fig. 2). Among the patients receiv-
ing apixaban, as compared with those receiving 
placebo, there were more events of fatal bleeding 
(5 vs. 0), intracranial bleeding (12 vs. 3), ISTH major 
or clinically relevant nonmajor bleeding (117 vs. 45), 
and total bleeding (679 vs. 305). Patients receiving 
apixaban received more transfusions than did pa-
tients receiving placebo (144 [3.9%] vs. 73 [2.0%]).
The findings with respect to the primary safety 
outcome were consistent among all key subgroups 
(Fig. 3 in the Supplementary Appendix). The in-
crease in bleeding events with apixaban, as com-
pared with placebo, was seen both in patients taking 
combination antiplatelet therapy (1.3% vs. 0.6%; 
hazard ratio, 2.27; 95% CI, 1.28 to 4.02) and in pa-
tients taking aspirin alone (1.1% vs. 0.1%), although 
there was only a small number of major bleeding 
events in the aspirin-only subgroup.
The frequencies of serious adverse events and 
overall adverse events were similar in the apixaban 
group and the placebo group (24.3% and 59.0%, 
respectively, in the apixaban group and 24.3% and 
57.7%, respectively, in the placebo group). The fre-
quencies of events other than ischemic events and 
bleeding were either similar in the two groups 
or lower in the apixaban group than in the pla-
cebo group (Table 1 in the Supplementary Appen-
dix). There were no significant between-group dif-
ferences in the rates of adverse events related to 
hepatotoxicity.
Discussion
In this randomized clinical trial, the oral factor 
Xa inhibitor apixaban, administered at a dose of 
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Figure 1. Kaplan–Meier Curves for the Primary Efficacy Outcome.
The primary efficacy outcome was the composite of cardiovascular death, myocardial infarction, or ischemic stroke. 
An intention-to-treat analysis was used to compare patients assigned to apixaban with those assigned to placebo. 
The inset shows the same data on an enlarged y axis.
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5 mg twice daily in high-risk patients who were 
taking either aspirin or aspirin plus clopidogrel 
after an acute coronary syndrome, resulted in a 
significant increase in bleeding events, including 
increases in events of fatal and intracranial bleed-
ing, without a significant reduction in recurrent is-
chemic events. These findings were consistent in 
all subgroups, including subgroups defined accord-
ing to antiplatelet therapy (aspirin plus clopid ogrel 
vs. aspirin alone) and according to management of 
the acute coronary syndrome (revascularization vs. 
noninvasive management). The increase in bleed-
ing with apixaban led more frequently to discon-
tinuation of the study drug and resulted in the pre-
Table 2. Clinical Outcomes.*
Outcome Apixaban Placebo
Hazard Ratio with 
Apixaban (95% CI) P Value
Total Event Rate Total Event Rate
no. of patients 
(%)
no. of events/ 
100 patient-yr
no. of patients 
(%)
no. of events/ 
100 patient-yr
Efficacy 3705 (100) 3687 (100)
Cardiovascular death, myocardial 
 infarction, or ischemic stroke
279 (7.5) 13.2 293 (7.9) 14.0 0.95 (0.80–1.11) 0.51
Cardiovascular death, myocardial 
 infarction, ischemic stroke, 
or  unstable angina
352 (9.5) 16.9 370 (10.0) 18.0 0.94 (0.82–1.09) 0.43
Death 155 (4.2) 7.1 143 (3.9) 6.6 1.08 (0.86–1.35) 0.51
Cardiovascular death 105 (2.8) 4.8 109 (3.0) 5.0 0.96 (0.73–1.25) 0.76
Myocardial infarction 182 (4.9) 8.6 194 (5.3) 9.2 0.93 (0.76–1.14) 0.51
Ischemic stroke 23 (0.6) 1.1 34 (0.9) 1.6 0.68 (0.40–1.15) 0.14
Unstable angina 85 (2.3) 4.0 90 (2.4) 4.2 0.94 (0.70–1.26) 0.67
Stent thrombosis 35 (0.9) 1.6 48 (1.3) 2.2 0.73 (0.47–1.12) 0.15
Safety: bleeding† 3673 (100) 3642 (100)
TIMI criteria
Major bleeding 46 (1.3) 2.4 18 (0.5) 0.9 2.59 (1.50–4.46) 0.001
Major or minor bleeding 80 (2.2) 4.2 29 (0.8) 1.5 2.79 (1.83–4.27) <0.001
ISTH criteria
Major bleeding 98 (2.7) 5.1 40 (1.1) 2.0 2.48 (1.72–3.58) <0.001
Major or clinically relevant non-
major bleeding
117 (3.2) 6.2 45 (1.2) 2.3 2.64 (1.87–3.72) <0.001
GUSTO criteria
Severe bleeding 36 (1.0) 1.8 12 (0.3) 0.6 3.05 (1.59–5.86) 0.001
Severe or moderate bleeding 83 (2.3) 4.3 25 (0.7) 1.3 3.37 (2.16–5.27) <0.001
Fatal bleeding 5 (0.1) 0.3 0 NA NA NA
Intracranial bleeding 12 (0.3) 0.6 3 (0.1) 0.2 4.06 (1.15–14.38) 0.03
Any bleeding 679 (18.5) 40.1 305 (8.4) 14.4 2.36 (2.06–2.70) <0.001
Net clinical outcomes 3705 (100) 3687 (100)
Cardiovascular death, myocardial 
 infarction, ischemic or hemor-
rhagic stroke, or fatal bleeding
295 (8.0) 14.0 299 (8.1) 14.3 0.98 (0.83–1.15) 0.80
Death, myocardial infarction, or is-
chemic or hemorrhagic stroke
327 (8.8) 15.5 328 (8.9) 15.6 0.99 (0.85, 1.15) 0.90
* GUSTO denotes Global Use of Strategies to Open Occluded Coronary Arteries, ISTH International Society on Thrombosis and Haemostasis, 
NA not applicable, and TIMI Thrombolysis in Myocardial Infarction.
† The safety outcomes were assessed in an analysis of data from patients who received at least one dose of the study drug.
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mature termination of the trial — both of which 
limit the certainty of the conclusions that can be 
drawn about efficacy.
The current standard of care for patients after 
an acute coronary syndrome includes dual anti-
platelet therapy, typically with aspirin and clo-
pid ogrel.23,27 Despite aggressive use of dual anti-
platelet therapy, however, patients frequently have 
recurrent ischemic events. Newer, more potent 
P2Y12-receptor antagonists provide additional re-
ductions in ischemic events2 and mortality3 but 
at the cost of an increase in bleeding. Thus, pa-
tients with a substantial risk of recurrent events 
have an important unmet need for better second-
ary prevention.28 A combination of antiplatelet 
and anticoagulant agents seems to be an attrac-
tive approach. However, such broad antithrom-
botic therapy may also pose an unacceptable risk 
of bleeding.7,29
In this trial, we enrolled a high-risk patient 
population, with large proportions of patients 
who had diabetes, heart failure, or renal insuf-
ficiency, as well as a large proportion of patients 
who did not undergo revascularization for the 
index event.2,3,22,30-34 We hypothesized that this 
population was most likely to benefit from the 
addition of an oral anticoagulant agent in addi-
tion to standard antiplatelet and other evidence-
based therapies. Further investigation is required 
to determine whether there are other patient popu-
lations for which the results may be different or 
concomitant interventions that might change 
the risk–benefit profile of the combination of 
anticoagulation plus antiplatelet therapy in this 
population.
Three phase 2 clinical trials have investigated 
the use of new oral anticoagulant drugs in addi-
tion to contemporary antiplatelet therapy in pa-
tients who have had a recent acute coronary syn-
drome.16,17,35 When added to antiplatelet therapy, 
both apixaban and riva rox aban resulted in dose-
related increases in bleeding but also appeared 
to result in larger absolute reductions in ische-
mic events than those seen with placebo. The in-
creases in bleeding were smaller and the reduc-
tions in ischemic events were more pronounced 
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Figure 2. Kaplan–Meier Curves for the Primary Safety Outcome.
The primary safety outcome was major bleeding according to the Thrombolysis in Myocardial Infarction (TIMI) definition. 
An on-treatment analysis was used to compare patients who received at least one dose of apixaban with those who 
 received at least one dose of placebo. The inset shows the same data on an enlarged y axis.
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among patients taking aspirin alone than among 
those taking aspirin plus clopidogrel. The findings 
from the APPRAISE-2 trial definitively confirm the 
increases in bleeding observed in the phase 2 trials 
of factor Xa inhibitors administered in addition to 
antiplatelet therapy. Unfortunately, the reductions 
in ischemic events suggested in the phase 2 trial 
were not observed in this larger phase 3 trial. 
Because this trial was stopped early owing to the 
increase in bleeding events, with fewer ischemic 
events having occurred than the number planned, 
uncertainty remains regarding the effect of apixa-
ban on ischemic events. The ATLAS-ACS 2 TIMI 
51 trial (Anti-Xa Therapy to Lower Cardiovascu-
lar Events in Addition to Standard Therapy in 
Subjects with Acute Coronary Syndrome–Throm-
bolysis in Myocardial Infarction 51; ClinicalTrials 
.gov number, NCT00402597), which includes a 
lower-risk population than that in the APPRAISE-2 
trial and is evaluating two different doses of an-
other factor Xa inhibitor, is currently ongoing.36 
Whether this trial will have similar results remains 
to be seen.
Meta-analyses of earlier studies with oral vi-
tamin K antagonists combined with aspirin, as 
compared with aspirin alone, showed that there 
were reductions in recurrent ischemic events in 
patients after acute coronary syndromes.4,5 In a 
large, observational analysis that included more 
than 40,000 patients with myocardial infarction, 
the use of triple therapy (aspirin, clopidogrel, and 
a vitamin K antagonist), as compared with aspirin 
alone, was associated with a rate of bleeding that 
was increased by a factor of 4, with no significant 
difference in the rate of survival.29 Similar increases 
in bleeding events have been seen in other studies 
and other clinical settings in which the use of 
combined antiplatelet and anticoagulant therapy 
may be considered.7 The results of the current 
trial raise doubt about whether meaningful incre-
mental efficacy can be achieved with an accept-
able risk of bleeding by combining a long-term 
oral anticoagulant with both aspirin and a P2Y12-
receptor antagonist in patients with coronary 
disease.
In summary, we evaluated the addition of apix-
aban, at a dose of 5 mg twice daily, to standard 
antiplatelet therapy in patients with an acute coro-
nary syndrome. Treatment with apixaban, as com-
pared with placebo, was associated with a signifi-
cant increase in the risk of bleeding, without a 
significant effect on the incidence of recurrent 
ischemic events.
Supported by Bristol-Myers Squibb and Pfizer.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
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